Firstly, when comparing CLL patients grouped according to CD38 expression, CD14+HLA-DRlow/− MDSC levels in CD38low and CD38high CLL patients were significantly higher compared with the control group (both P<0.0001). The gene discussed is CD38; the disease is B-cell chronic lymphocytic leukemia.